CORVUS PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

23 Jan 2026 09:46:10 提供 NetDania Notify

NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

22 Jan 2026 09:45:01 提供 NetDania Notify

NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

21 Jan 2026 09:45:19 提供 NetDania Notify

NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

20 Jan 2026 09:46:23 提供 NetDania Notify

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

16 Jan 2026 16:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference

05 Jan 2026 08:30:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial

08 Dec 2025 10:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

08 Dec 2025 09:50:48 提供 NetDania Notify

NetDania - New 12 months High: CORVUS PHARMACEUTICALS INC. - COMMON STOCK

05 Dec 2025 10:30:25 提供 NetDania Notify

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

04 Nov 2025 16:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition

03 Nov 2025 09:02:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

31 Oct 2025 07:30:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

28 Oct 2025 16:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

17 Oct 2025 10:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

02 Oct 2025 16:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

07 Aug 2025 16:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025

31 Jul 2025 16:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

25 Jun 2025 08:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

11 Jun 2025 07:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

04 Jun 2025 07:00:00 提供 Nasdaq GlobeNewswire